MX2014005749A - Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). - Google Patents
Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp).Info
- Publication number
- MX2014005749A MX2014005749A MX2014005749A MX2014005749A MX2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A MX 2014005749 A MX2014005749 A MX 2014005749A
- Authority
- MX
- Mexico
- Prior art keywords
- mmp
- nanocarriers
- diagnostic
- targeted therapeutic
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
La presente invención se refiere a composiciones de administración dirigida que comprende inhibidores de metaloproteinasa de matriz (MMP) y a métodos para usar la composiciones para tratar y diagnosticar un estado de enfermedad en un sujeto.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161565461P | 2011-11-30 | 2011-11-30 | |
PCT/US2012/067236 WO2013082389A1 (en) | 2011-11-30 | 2012-11-30 | Mmp-targeted therapeutic and/or diagnostic nanocarriers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014005749A true MX2014005749A (es) | 2014-06-05 |
Family
ID=47430071
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014005749A MX2014005749A (es) | 2011-11-30 | 2012-11-30 | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). |
Country Status (11)
Country | Link |
---|---|
US (2) | US8871189B2 (es) |
EP (1) | EP2785635A1 (es) |
JP (1) | JP2015502946A (es) |
KR (2) | KR20140096080A (es) |
CN (1) | CN104080729A (es) |
BR (1) | BR112014012746A8 (es) |
CA (1) | CA2854194A1 (es) |
IL (1) | IL232824A0 (es) |
MX (1) | MX2014005749A (es) |
RU (1) | RU2014123622A (es) |
WO (1) | WO2013082389A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140271465A1 (en) * | 2013-03-15 | 2014-09-18 | Mallinckrodt Llc | Matrix metalloprotease (mmp) targeted agents for imaging and therapy |
CA2882268A1 (en) * | 2014-02-17 | 2015-08-17 | The Royal Institution For The Advancement Of Learning / Mcgill University | Polynucleotide-poly(diol) conjugates, process of preparation and uses thereof |
US20160058705A1 (en) * | 2014-08-28 | 2016-03-03 | Jayakumar Rajadas | Compositions and methods for treating cardiovascular and pulmonary diseases and disorders with apelin |
KR101683463B1 (ko) * | 2014-12-19 | 2016-12-08 | 서울대학교산학협력단 | 마이크로버블-리포좀-멜라닌 나노입자 복합체 및 이를 포함하는 조영제 |
RU2646752C2 (ru) * | 2016-02-25 | 2018-03-07 | Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" | Ингибиторы цинк-зависимых металлопротеиназ (ММП-2 и ММП-9) в ряду бензоиламино(фенилсульфонил)-замещенных циклических аминокислот как потенциальные лекарственные средства, препятствующие постинфарктному ремоделированию левого желудочка сердца |
KR20190075968A (ko) | 2016-10-19 | 2019-07-01 | 어바이브, 인크. | 심혈관-관련 질환의 치료를 위한 아펠린의 신규 peg화 리포솜 제제 |
CN111004195B (zh) * | 2019-12-03 | 2022-01-28 | 沈阳药科大学 | 卡巴他赛弱碱性衍生物及其制剂 |
US11801304B2 (en) | 2020-02-19 | 2023-10-31 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225181A (en) * | 1985-06-07 | 1993-07-06 | The Research Foundation Of State University Of New York | Radiolabeled antiplatelet monoclonal antibody for imaging in-vivo thrombi |
US6750228B1 (en) * | 1997-11-14 | 2004-06-15 | Pharmacia Corporation | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
FI113840B (fi) * | 2001-03-26 | 2004-06-30 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa |
FI20031528A0 (fi) | 2003-10-17 | 2003-10-17 | Ctt Cancer Targeting Tech Oy | Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi |
GB0326546D0 (en) * | 2003-11-14 | 2003-12-17 | Amersham Plc | Inhibitor imaging agents |
US20060210549A1 (en) | 2004-09-10 | 2006-09-21 | Srivastava Devendra K | Controlled release liposomes and methods of use |
EP1862470A4 (en) | 2005-02-25 | 2010-04-21 | Univ Hokkaido Nat Univ Corp | ELEMENT RETAINED IN BLOOD SHOWING SELECTIVE DEGRADABILITY IN TUMOR TISSUE |
EP1998684A4 (en) | 2006-03-10 | 2014-09-17 | Massachusetts Inst Technology | CONJUGATES AND NANOSYSTEMS WITH TRIGGERED SELF ASSEMBLY |
US7618992B2 (en) * | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
WO2010012473A2 (en) | 2008-07-30 | 2010-02-04 | Charite - Universitätsmedizin Berlin | Hydrolase-specific nanosensors, methods for producing them and uses in molecular imaging |
WO2010022051A2 (en) | 2008-08-18 | 2010-02-25 | University Of Kansas | Disruptors of early/recycling endosomes |
EP2416763A4 (en) | 2009-04-06 | 2015-05-06 | Mayo Foundation | METHODS AND SUBSTANCES FOR DELIVERING MOLECULES |
EP2454271A4 (en) | 2009-07-15 | 2015-08-12 | Univ California | PEPTIDES WITH CONTROLLABLE CELLULAR RECORDING |
WO2011139343A2 (en) * | 2010-04-28 | 2011-11-10 | Wu Nian | Amino acid linked peg-lipid conjugates |
-
2012
- 2012-11-29 US US13/689,694 patent/US8871189B2/en not_active Expired - Fee Related
- 2012-11-30 CN CN201280067193.1A patent/CN104080729A/zh active Pending
- 2012-11-30 EP EP12806235.3A patent/EP2785635A1/en not_active Withdrawn
- 2012-11-30 RU RU2014123622A patent/RU2014123622A/ru not_active Application Discontinuation
- 2012-11-30 KR KR1020147014186A patent/KR20140096080A/ko not_active Application Discontinuation
- 2012-11-30 KR KR1020157024031A patent/KR20150107894A/ko not_active Application Discontinuation
- 2012-11-30 JP JP2014544914A patent/JP2015502946A/ja active Pending
- 2012-11-30 MX MX2014005749A patent/MX2014005749A/es unknown
- 2012-11-30 BR BR112014012746A patent/BR112014012746A8/pt not_active IP Right Cessation
- 2012-11-30 WO PCT/US2012/067236 patent/WO2013082389A1/en active Application Filing
- 2012-11-30 CA CA2854194A patent/CA2854194A1/en not_active Abandoned
-
2014
- 2014-05-27 IL IL232824A patent/IL232824A0/en unknown
- 2014-09-18 US US14/490,357 patent/US20150004097A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104080729A (zh) | 2014-10-01 |
EP2785635A1 (en) | 2014-10-08 |
US8871189B2 (en) | 2014-10-28 |
KR20140096080A (ko) | 2014-08-04 |
US20150004097A1 (en) | 2015-01-01 |
JP2015502946A (ja) | 2015-01-29 |
BR112014012746A8 (pt) | 2017-06-20 |
CA2854194A1 (en) | 2013-06-06 |
US20130183236A1 (en) | 2013-07-18 |
RU2014123622A (ru) | 2016-01-27 |
WO2013082389A1 (en) | 2013-06-06 |
KR20150107894A (ko) | 2015-09-23 |
IL232824A0 (en) | 2014-07-31 |
BR112014012746A2 (pt) | 2017-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014005749A (es) | Nanoportadores terapeuticos y/o de diagnostico, dirigidos a metaloproteinasa de matriz (mmp). | |
IL284530A (en) | RNAI factors, compositions and methods of using them for the treatment of transthyretin-related diseases | |
IN2014CN03465A (es) | ||
MY188365A (en) | Diagnosis and treatments relating to th2 inhibition | |
MX356525B (es) | Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia. | |
IN2014MN00948A (es) | ||
MX2013008851A (es) | Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias. | |
AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
TR201904980T4 (tr) | Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar. | |
EA201400165A1 (ru) | Частицы на основе полиакрилата, которые содержат активное соединение | |
MX348941B (es) | Medios y metodos para trata y/o prevenir el cancer dependiente del ligando natural de receptor de aril-hidrocarburo. | |
BR112013010136A2 (pt) | vacina, composição terapêutica e métodos para o tratamento ou inibição de gliblastoma | |
MX2013008175A (es) | Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos. | |
MX340536B (es) | Terapia direccionada al receptor del factor de crecimiento epidermico (egfr). | |
HK1200708A1 (en) | Methods for diagnosing and treating alzheimers disease by administering an antiangiogenic agent | |
PH12014502065A1 (en) | Vesicular formulations | |
MX2013010367A (es) | Composiciones y metodos para la terapia y diagnostico de influenza. | |
TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
SG194235A1 (en) | Methods of predicting the development of complement-mediated disease | |
MX2014008194A (es) | Cefovecina util en el tratamiento de la enfermedad de lyme. | |
BR112012006073A2 (pt) | composições e métodos para tratar espasticidade. | |
TN2013000247A1 (en) | Compositions comprising a pi3k inhibitor and a mek inhibitor and their use for treating cancer | |
TR201200215A2 (tr) | Geliştirilmiş farmasötik formülasyonlar. | |
TR201200211A2 (tr) | Risedronat içeren farmasötik granüller. | |
GB201111427D0 (en) | Novel bisindolylmaleimides, pan-pkc inhibitors |